PartnershipProvides Long Islanders with Direct Access to World-Class Team Treating Advanced Heart Failure with Transplants and Implanted Heart-Assist Devices
NYU Winthrop Hospital recently declared that effective right away, it is offering the world-class heart transplant services of NYU Langone Health to NYU Winthrop patients on Long Island. Heart transplant services will be led by esteemed cardiothoracic surgeon Nader Moazami, MD, who joined NYU Langone earlier this year from the Cleveland Clinic. Dr. Moazami, who has performed more than 300 heart transplants, adds to a highly skilled team already serving NYU Winthrop patients. Services on Long Island will include pre-surgical evaluations of candidates for implanted heart-assist devices and heart transplants. These new services come at an especially opportune time for NYU Winthrop, given that heart disease and stroke are among the top health concerns among Long Islanders.
“We’re bringing the world-class services of NYU Langone’s heart transplant program to our patients locally on Long Island, further elevating our already strong cardiology services,” said Kevin Marzo, MD, Chief of the Cardiology Division at NYU Winthrop. “Patients with advanced heart failure often have reduced mobility, so this new partnershipvastly increases patient access. Long Islanders need look no further than their own backyard for the finest in heart care.”
The NYU Langone-NYU Winthrop collaborative services will be conducted in Mineola, while the actual heart transplants or implantation of heart-assist devices, such as left ventricular heart assist devices (LVAD), will be performed at NYU Langone Medical Center in New York City.
“We’re creating an integrated system between NYU Langone and NYU Winthrop so that a patient in need of therapies for end-stage heart failure encounters a seamless process,” added Nader Moazami, MD, Surgical Director of Heart Transplantation and Mechanical Circulatory Support at NYU Langone Health. “Already, we’re seeing an exceptionally strong spirit of partnershipin our efforts, working toward the most successful patient outcomes possible.”
Assisting to lead this collaborative team is also Alex Reyentovich, MD, Medical Director of the Heart Transplant and Ventricular Assist Device Program at NYU Langone Health. Dr. Reyentovich and his team of fellowship-trained heart failure specialists, have extensive experience in treating patients with advanced heart disease and LVADs.
LVADs are an option for a patient whose heart can no longer pump enough blood to meet the body’s needs. The assistive devices are used in three ways: as a bridge until a transplant donor is found; to stabilize the heart until the muscle might recover; and as a “destination therapy,” i.e. a permanent solution for a person with contraindications to a heart transplant such as kidney disease or advanced age.
NYU Winthrop’s Division of Cardiology is committed to providing the very best, comprehensive care for Long Island residents with cardiovascular disease. The addition of a heart transplantation program to existing specialties facilitates patients to receive even more comprehensive care close to home. The Hospital also receives accolades as a national leader in Transcatheter Aortic Valve Replacement (TAVR). TAVR is a revolutionary procedure that facilitates patients with severe aortic stenosis to receive a new heart valve without undergoing open-heart surgery. Last year, NYU Winthrop was among the top five busiest hospitals in the nation performing this minimally invasive FDA-approved procedure.
